Cocrystal Pharma, Inc. COCP

Company Overview

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for infectious diseases. The company operates within the biopharmaceutical and drug development industries, with a primary emphasis on small-molecule antiviral drug candidates targeting viral replication mechanisms. Its research programs have historically focused on influenza, COVID-19, norovirus, and hepatitis C virus (HCV), with revenue generation primarily tied to licensing arrangements, collaboration agreements, and financing activities rather than commercialized product sales.

The company’s strategy is centered on structure-based drug discovery technology designed to develop broad-spectrum antiviral compounds that target highly conserved regions of viral proteins. Cocrystal Pharma was formed in 2014 through a merger involving Biozone Pharmaceuticals and Cocrystal Discovery, Inc., after which the company adopted the Cocrystal Pharma name and shifted its strategic focus toward antiviral therapeutics. The company has positioned itself as a specialized antiviral developer leveraging computational chemistry, structural biology, and medicinal chemistry capabilities to pursue therapies intended to reduce the risk of viral resistance.